Jay Parrish
Chief Executive Officer at Pretzel Therapeutics, Inc.
Profile
Jay Parrish, Ph.D.
is a Venture Partner at ARCH Venture Partners and Chairman of Pretzel Therapeutics, a company focused on developing first-in-class therapeutics addressing mitochondrial dysfunction.
Previously, he was co-founder and Chief Business Officer of Vir Biotechnology, a company focused on infectious disease.
As Vir’s first employee, he helped lead the company through its IPO and first drug approval.
At ARCH, Dr. Parrish is a board member of Interline Therapeutics, co-founder and board member of Rome Therapeutics, and advises companies throughout the portfolio.
Dr. Parrish is an accomplished scientist who began his career at Gilead Sciences, Inc. in the Medicinal Chemistry group where his research focused on the discovery of small molecule anti-virals for the treatment of HIV, hepatitis C, and respiratory syncytial viruses.
In this role, he was involved with several successful discovery campaigns, including being a co-inventor of ledipasvir (Harvoni®), approved as a cure for hepatitis C genotypes 1, 4–6, and remdesivir (Veklury®), approved for COVID-19.
Dr. Parrish has authored over 25 peer-reviewed scientific publications and holds over 30 issued patents.
After nearly a decade in research, Dr. Parrish joined Gilead’s Corporate Development team, where he was involved in building Gilead’s oncology and infectious disease portfolio, ultimately leading infectious disease business development for the company.
Dr. Parrish holds a B.S.
in Chemistry from Emory University and a Ph.D.
in Synthetic Organic Chemistry from the University of South Florida.
He completed a Postdoctoral Fellowship at the Scripps Research Institute and received an M.B.A.
from U.C.
Berkeley’s Haas School of Business.
Jay Parrish active positions
| Companies | Position | Start |
|---|---|---|
ARCH Venture Partners LLC
 ARCH Venture Partners LLC Investment ManagersFinance ARCH Venture Partners LLC is a Venture Capital firm founded in 1986. The firm is headquartered in Chicago with additional office in Dublin. | Private Equity Analyst | 2016-04-30 |
Rome Therapeutics, Inc.
 Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | Founder | 2019-04-30 |
Pretzel Therapeutics, Inc.
 Pretzel Therapeutics, Inc. BiotechnologyHealth Technology Pretzel Therapeutics, Inc. is an American biotechnology company that develops therapies by utilizing mitochondrial biology. Pretzel Therapeutics is based in an undisclosed location and has research facilities in another undisclosed location. The company aims to develop treatments that address the genetic causes of mitochondrial dysfunction. The company was founded by academic experts in mitochondrial biology and is supported by a world-class investor syndicate. Jay Parrish has been the CEO of the company since 2021. | Chief Executive Officer | 2021-03-31 |
Orbital Therapeutics, Inc.
 Orbital Therapeutics, Inc. BiotechnologyHealth Technology Orbital Therapeutics, Inc. is a company based in Cambridge, MA that aims to enhance health by utilizing RNA-based medicines to treat human diseases in innovative ways. The company is building a platform that combines RNA technology delivery methods, data science, and automation to develop a portfolio of medicines focused on vaccines, immunomodulation, protein replacement, and regenerative medicine. The company was founded by Drew Weissman, John M. Maraganore, Kristina M. Burow, Ravindra Majeti, Giuseppe Ciaramella, Eugene W. Yeo, Howard Y. Chang, and Carol Suh, with Giuseppe Ciaramella serving as the CEO since incorporation. | Consultant / Advisor | 2022-05-31 |
Interline Therapeutics, Inc.
 Interline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Interline Therapeutics is an American drug discovery company that focuses on understanding protein communities to define molecular mechanisms of disease. The company is based in California and was incubated by Foresite Labs. Interline Therapeutics is developing new drugs that target key drivers of inflammation and cancer. The CEO of the company is Zachary Sweeney. | Director/Board Member | 2021-04-30 |
Former positions of Jay Parrish
| Companies | Position | End |
|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Founder | 2021-03-31 |
Guide Therapeutics, Inc.
 Guide Therapeutics, Inc. BiotechnologyHealth Technology Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA. | Director/Board Member | 2021-01-31 |
Abide Therapeutics, Inc.
 Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Consultant / Advisor | 2011-03-31 |
Training of Jay Parrish
| Emory University | Undergraduate Degree |
| University of South Florida | Doctorate Degree |
| Haas School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| VIR BIOTECHNOLOGY, INC. | Health Technology |
| Private companies | 7 |
|---|---|
ARCH Venture Partners LLC
ARCH Venture Partners LLC Investment ManagersFinance ARCH Venture Partners LLC is a Venture Capital firm founded in 1986. The firm is headquartered in Chicago with additional office in Dublin. | Finance |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Health Technology |
Guide Therapeutics, Inc.
Guide Therapeutics, Inc. BiotechnologyHealth Technology Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA. | Health Technology |
Rome Therapeutics, Inc.
Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | Health Technology |
Interline Therapeutics, Inc.
Interline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Interline Therapeutics is an American drug discovery company that focuses on understanding protein communities to define molecular mechanisms of disease. The company is based in California and was incubated by Foresite Labs. Interline Therapeutics is developing new drugs that target key drivers of inflammation and cancer. The CEO of the company is Zachary Sweeney. | Health Technology |
Pretzel Therapeutics, Inc.
Pretzel Therapeutics, Inc. BiotechnologyHealth Technology Pretzel Therapeutics, Inc. is an American biotechnology company that develops therapies by utilizing mitochondrial biology. Pretzel Therapeutics is based in an undisclosed location and has research facilities in another undisclosed location. The company aims to develop treatments that address the genetic causes of mitochondrial dysfunction. The company was founded by academic experts in mitochondrial biology and is supported by a world-class investor syndicate. Jay Parrish has been the CEO of the company since 2021. | Health Technology |
Orbital Therapeutics, Inc.
Orbital Therapeutics, Inc. BiotechnologyHealth Technology Orbital Therapeutics, Inc. is a company based in Cambridge, MA that aims to enhance health by utilizing RNA-based medicines to treat human diseases in innovative ways. The company is building a platform that combines RNA technology delivery methods, data science, and automation to develop a portfolio of medicines focused on vaccines, immunomodulation, protein replacement, and regenerative medicine. The company was founded by Drew Weissman, John M. Maraganore, Kristina M. Burow, Ravindra Majeti, Giuseppe Ciaramella, Eugene W. Yeo, Howard Y. Chang, and Carol Suh, with Giuseppe Ciaramella serving as the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Jay Parrish
